Roche is saying that Erivedge sold $=CHF13 M in Q1, 2012 royalties for CRIS were $1.5M. Projected 2013 sales are ~$60M (excluding EU or AU only US). the royalty for 2013 will be doubled. CRIS has to pay 5% of the $3M to the Academia. It is not too bad, I think that we can project 2015 WW revenues of $$20M to 30M. A major expansion into the new indication can double that.
With all these calculations, above $7 stock price will not be reachable this year. There will be a lot of hype by July and might take this to $8.
go look at a one year chart of INFI... they have no approved products and their rise was on their pi3k delta molecule... we have very similar product with a built in hdac molecule... curis is not a revenue story... erivedge helps pay the bills for cudc-907 and soon to be oral iap inhibitor that was created by genentech for phase 2 trials.